$Pegloticase: A Novel Agent for Treatment-Refractory Gout$

Pegloticase: A Novel Agent for Treatment-Refractory Gout

Objective: To evaluate efficacy and safety of pegloticase, approved by the Food and Drug Administration in September 2010 for treatment of patients with chronic treatment-refractory gout. Data Sources: Literature searches were conducted using PubMed (1948–January 2012), TOXLINE, international Pharma...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The Annals of pharmacotherapy 2012-03, Vol.46 (3), p.368-376
Hauptverfasser:	Shannon, Jennifer A, Cole, Sabrina W
Format:	Artikel
Sprache:	eng
Schlagworte:	Animals Biological and medical sciences Diseases of the osteoarticular system Enzymes, Immobilized - administration & dosage Enzymes, Immobilized - economics Enzymes, Immobilized - pharmacokinetics Gout - drug therapy Gout - metabolism Gout Suppressants - administration & dosage Gout Suppressants - economics Gout Suppressants - pharmacokinetics Health Expenditures Humans Inflammatory joint diseases Medical sciences Metabolic diseases Miscellaneous. Osteoarticular involvement in other diseases Other metabolic disorders Pharmacology. Drug treatments Polyethylene Glycols - administration & dosage Polyethylene Glycols - economics Polyethylene Glycols - pharmacokinetics Purines and pyrimidines (gout, hyperuricemia...) Urate Oxidase - administration & dosage Urate Oxidase - economics Urate Oxidase - pharmacokinetics
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!